The United States Patent and Trademark Office (USPTO) has issued a patent grant (US12583846B2) for a class of 2H-benzopyran derivatives that act as CRAC inhibitors. The patent specifically discloses compounds represented by a particular formula, including isomers and pharmaceutically acceptable salts, and their use in the preparation of CRAC inhibitors. The filing date for this patent was September 25, 2020, and the grant date is March 24, 2026.

This patent grant signifies the USPTO's recognition of novel intellectual property in the field of organic chemistry and drug development. While patent grants are non-binding regulatory instruments, they establish exclusive rights for the patent holder, impacting potential market entry and research and development activities for competing entities in the pharmaceutical sector. Companies involved in CRAC inhibitor research or related therapeutic areas should be aware of this granted patent to ensure freedom to operate and to inform their own R&D strategies.